Clinical trial
ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer
NCT00415779 · National Cancer Institute, Naples, Other · Completed
Key facts
| NCT number | NCT00415779 |
|---|---|
| Title | ZANTE: Zometa and Taxotere in Hormone Refractory Prostate Cancer |
| Official title | Phase I Study of the Combination of Zoledronic Acid and Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer |
| Acronym | ZANTE |
| Lead sponsor | National Cancer Institute, Naples, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Metastatic Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, zoledronic acid |
| Enrollment | 36 |
| Start date | Jul 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Jul 1, 2009 |
| First posted | Dec 25, 2006 |
| Last update posted | Feb 24, 2010 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: